COLGATE PALMOLIVE CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that COLGATE PALMOLIVE CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $15.45B | Feb 21, 2018 |
| FY2017 | Dec 31, 2016 | $15.20B | Feb 21, 2018 |
| FY2017 | Dec 31, 2015 | $16.03B | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $17.28B | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $17.42B | Feb 18, 2016 |
| FY2014 | Dec 31, 2012 | $17.09B | Feb 19, 2015 |
| FY2013 | Dec 31, 2011 | $16.73B | Feb 20, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.38B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $20.10B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $19.46B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $17.97B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $17.42B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $4.32B | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $4.15B | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $3.90B | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $4.10B | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $4.02B | Feb 18, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.89B | Feb 21, 2018 |
| FY2017 | Sep 30, 2017 | $3.97B | Feb 21, 2018 |
| FY2017 | Jun 30, 2017 | $3.83B | Feb 21, 2018 |
| FY2017 | Mar 31, 2017 | $3.76B | Feb 21, 2018 |
| FY2017 | Dec 31, 2016 | $3.72B | Feb 21, 2018 |
| FY2017 | Sep 30, 2016 | $3.87B | Feb 21, 2018 |
| FY2017 | Jun 30, 2016 | $3.85B | Feb 21, 2018 |
| FY2017 | Mar 31, 2016 | $3.76B | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | $3.90B | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $4.00B | Feb 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.25B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $12.16B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $11.33B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $10.25B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $10.38B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $2.64B | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $2.54B | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $2.37B | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $2.47B | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $2.41B | Feb 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.13B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.89B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $2.30B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $1.79B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.17B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $647.00M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $698.00M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $635.00M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $715.00M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $643.00M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.31B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.27B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $3.98B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $2.89B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.33B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $3.89B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $3.55B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $3.69B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $3.71B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $3.96B | Feb 21, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.00M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $355.00M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $343.00M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $320.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $307.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $290.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $281.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $277.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $285.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $289.00M | Feb 21, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.90B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $7.73B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $7.15B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $6.57B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $6.41B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $6.02B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $5.58B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $5.39B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $5.40B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $5.14B | Feb 21, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.20B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $4.11B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $3.75B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $2.56B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.33B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $3.72B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $3.13B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $3.06B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $3.05B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $3.14B | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $696.00M | Feb 16, 2023 |
| FY2022 | Dec 31, 2021 | $567.00M | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $409.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $335.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $436.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $553.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $593.00M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $691.00M | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $757.00M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $670.00M | Feb 18, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.33B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $16.05B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $16.39B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $15.73B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $15.04B | Feb 16, 2023 |
| FY2022 | Dec 31, 2020 | $15.92B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $15.03B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $12.16B | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $12.68B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $12.12B | Feb 21, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.97B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $15.50B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $15.44B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $14.93B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $14.07B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $14.82B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $14.48B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $11.96B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $12.43B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $12.11B | Feb 21, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.00M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $212.00M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $609.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $401.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $609.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $743.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $117.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | ($102.00M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($60.00M) | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | ($243.00M) | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.12B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $3.27B | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $3.41B | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $3.35B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $3.28B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $3.82B | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $3.51B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $2.53B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $2.22B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $2.11B | Feb 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.60B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $26.15B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $25.29B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $24.57B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $24.35B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $23.70B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $22.50B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $21.62B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $20.53B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $19.92B | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $966.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $775.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $832.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $888.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $883.00M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $726.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.54B | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $1.32B | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.84B | Feb 23, 2026 |
| FY2024 | Dec 31, 2024 | $7.01B | Feb 13, 2025 |
| FY2018 | Dec 31, 2018 | $6.35B | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $6.57B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $6.52B | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | $6.54B | Feb 23, 2017 |
| FY2015 | Dec 31, 2014 | $6.13B | Feb 18, 2016 |
| FY2014 | Dec 31, 2013 | $5.64B | Feb 19, 2015 |
| FY2013 | Dec 31, 2012 | $5.18B | Feb 20, 2014 |
| FY2012 | Dec 31, 2011 | $4.78B | Feb 21, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 801.24M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 812.57M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | 821.41M | Feb 23, 2026 |
| FY2025 | Dec 31, 2022 | 830.21M | Feb 23, 2026 |
| FY2024 | Dec 31, 2021 | 840.48M | Feb 13, 2025 |
| FY2023 | Dec 31, 2020 | 849.89M | Feb 15, 2024 |
| FY2022 | Dec 31, 2019 | 854.70M | Feb 16, 2023 |
| FY2021 | Dec 31, 2018 | 862.91M | Feb 17, 2022 |
| FY2020 | Dec 31, 2017 | 874.70M | Feb 18, 2021 |
| FY2019 | Dec 31, 2016 | 883.11M | Feb 21, 2020 |